What you'll learn

• What Carlsson et al. (2000) meant by “network interactions” in schizophrenia.
• Why the study challenges a simple dopamine-only explanation.
• How dopamine, glutamate and GABA may interact in symptoms and treatment.
• How to evaluate Carlsson et al. for AO3, including methodology, ethics and applications.

Where this study fits

Carlsson et al. (2000), “Network interactions in schizophrenia — therapeutic implications”, is the contemporary study for schizophrenia in Edexcel A-Level Psychology 9PS0.

It is different from many named studies because it is not a lab experiment with one set of participants. It is a review paper: the authors considered existing biological evidence and used it to build a more complex explanation of schizophrenia and its treatment.

Prerequisite: what schizophrenia involves

Schizophrenia is a serious mental disorder involving disturbances in perception, thinking, emotion and behaviour. Diagnosis is usually based on classification systems such as the DSM or ICD, which list symptom patterns clinicians use to decide whether someone meets criteria.

A key issue for biological explanations is that schizophrenia is not just one symptom. A theory that explains hallucinations but cannot explain negative symptoms or cognitive problems is incomplete.

Prerequisite: neurotransmitters and receptors

A neuron is a nerve cell. Neurons communicate across tiny gaps called synapses using chemical messengers called neurotransmitters.

A receptor is a specialised site on a neuron that a neurotransmitter can bind to. When a neurotransmitter binds to a receptor, it changes the activity of the receiving neuron.

For Carlsson et al., the most important neurotransmitters are:

• Dopamine — linked to reward, motivation and psychosis; high dopamine activity has often been linked to positive symptoms.
• Glutamate — the brain’s main excitatory neurotransmitter, meaning it tends to increase neural activity.
• GABA — the brain’s main inhibitory neurotransmitter, meaning it tends to reduce neural activity.

Carlsson et al. also focus on the NMDA receptor, a type of glutamate receptor involved in learning, memory and complex brain signalling.

The background: why dopamine alone was not enough

Before Carlsson et al., schizophrenia was often explained using the dopamine hypothesis. This argued that schizophrenia, especially positive symptoms such as hallucinations and delusions, was linked to excessive dopamine activity.

There was some good evidence for this:

• Drugs such as amphetamines, which increase dopamine activity, can produce psychosis-like symptoms.
• Traditional antipsychotic drugs often block dopamine D2 receptors.
• These drugs are usually better at reducing positive symptoms than negative symptoms.

However, the simple dopamine hypothesis had problems. It struggled to explain why antipsychotic effects are delayed, why negative and cognitive symptoms often remain, and why some patients respond poorly to dopamine-blocking drugs.

Carlsson et al. (2000): aim and method

Aim

Carlsson et al. aimed to review evidence about how different neurotransmitter systems interact in schizophrenia and what this means for treatment.

Their central question was not simply “is dopamine involved?” but rather:

How do dopamine, glutamate and other neurotransmitter systems influence each other in schizophrenia?

Method

Carlsson et al. reviewed existing evidence from several sources, including:

• drug studies involving antipsychotic medication
• evidence from drugs such as amphetamine, ketamine and PCP
• animal research on neurotransmitter systems
• clinical evidence from people with schizophrenia
• research on typical and atypical antipsychotic drugs

This means the study used secondary data rather than directly testing a new participant sample.

The network model

Carlsson et al. suggested that schizophrenia involves abnormal interaction between neurotransmitter systems rather than one isolated chemical imbalance.

The key idea is that glutamate, dopamine and GABA regulate each other. If glutamate signalling through NMDA receptors is too low, this may disturb the normal control of dopamine pathways.

Dopamine pathways

A dopamine pathway is a route in the brain where dopamine neurons communicate between areas.

Two pathways are especially useful for A-Level evaluation:

• The mesolimbic pathway, linked to emotion and reward, may show dopamine overactivity. This is associated with positive symptoms.
• The mesocortical pathway, linked to the prefrontal cortex and thinking, may show dopamine underactivity. This is associated with negative and cognitive symptoms.

This is important because it helps explain why schizophrenia can involve both “too much” and “too little” dopamine activity depending on the brain area.

Glutamate and NMDA hypofunction

Carlsson et al. placed strong emphasis on NMDA receptor hypofunction.

Evidence for this comes partly from drugs such as PCP and ketamine, which block NMDA receptors. These drugs can produce schizophrenia-like symptoms in healthy people and can worsen symptoms in people with schizophrenia. Importantly, they can affect positive, negative and cognitive symptoms, making glutamate a useful addition to the dopamine explanation.

GABA and inhibition

GABA helps inhibit or “brake” neural activity. Carlsson et al. suggested that if glutamate and GABA systems are disrupted, they may fail to regulate dopamine properly.

So, dopamine abnormalities may be a downstream effect of wider network disruption.

Therapeutic implications

The phrase therapeutic implications means what the explanation suggests for treatment.

If schizophrenia involves several interacting neurotransmitters, then treatment should not focus only on blocking dopamine. Carlsson et al. argued that future treatments may need to target multiple transmitter systems.

Typical and atypical antipsychotics

Typical antipsychotics mainly reduce dopamine activity, especially by blocking D2 receptors. They are often helpful for positive symptoms but less effective for negative and cognitive symptoms.

Atypical antipsychotics, such as clozapine, affect dopamine but also act on other receptor systems. This fits Carlsson et al.’s network view because it suggests that broader neurotransmitter action may produce better therapeutic effects for some patients.

Main conclusions of the study

Carlsson et al. concluded that:

1. Schizophrenia is unlikely to be caused by a single dopamine abnormality.
2. Glutamate dysfunction, especially NMDA receptor hypofunction, may be central.
3. Dopamine abnormalities may differ across brain areas, helping explain different symptom types.
4. Treatments should target interacting networks rather than one neurotransmitter in isolation.

AO3 evaluation

Strength: broader explanatory power

A major strength is that the model explains more symptoms than the traditional dopamine hypothesis. Dopamine overactivity can help explain hallucinations and delusions, but glutamate and NMDA dysfunction may also help explain negative and cognitive symptoms.

This gives the study strong theoretical value because schizophrenia is a varied disorder.

Strength: real-world application

The study has clear treatment implications. It supports the development of drugs that affect more than one neurotransmitter system. This is useful because many patients do not fully respond to typical dopamine-blocking antipsychotics.

It also helps explain why atypical antipsychotics may be useful: they often have broader receptor effects.

Strength: converging evidence

Carlsson et al. used evidence from several areas, including drug effects, clinical treatment and animal studies. When different types of evidence point in a similar direction, this can strengthen confidence in the theory.

Weakness: review method and selection bias

Because Carlsson et al. was a review, the authors did not directly control variables, randomly allocate participants or collect new primary data. This means it cannot establish cause and effect in the same way as a well-controlled experiment.

There is also a risk of selection bias, where the evidence chosen may support the authors’ preferred interpretation more than contradictory evidence.

Weakness: no direct statistical test

This study does not report one main inferential test. So you should not claim that Carlsson et al. used Mann-Whitney U, Wilcoxon signed-ranks, Spearman’s rho or chi-square. Those tests are used for primary data on differences, correlations or associations, with observed values compared to critical values, often using a significance level such as $p\le .05$.

For Carlsson et al., the stronger evaluation is about whether the reviewed evidence is valid, consistent and representative.

Weakness: evidence can be indirect

Some evidence comes from drugs such as ketamine or PCP. These can produce schizophrenia-like symptoms, but a drug-induced state is not identical to naturally occurring schizophrenia. This limits how far the findings can be generalised.

Animal research is also useful for understanding mechanisms but cannot fully model human experiences such as delusions.

Weakness: biological reductionism

Carlsson et al. is less reductionist than a simple dopamine explanation because it considers networks. However, it is still mainly biological. It gives less attention to psychological and social factors such as trauma, family dysfunction, cognitive biases or stress.

A balanced essay can argue that Carlsson et al. is valuable, but not a complete explanation of schizophrenia.

Ethics

Carlsson et al. did not directly recruit participants, so issues such as consent, deception, right to withdraw, protection from harm, confidentiality and debrief apply mainly to the original studies they reviewed.

However, the ethical angle still matters. Research involving patients with schizophrenia must follow the BPS Code of Ethics and Conduct (2009), especially because participants may be vulnerable. Drug studies involving ketamine, PCP-like effects or antipsychotics require careful informed consent, protection from harm, the right to withdraw, confidentiality and a full debrief. Any deception would need strong justification and safeguards.

There is also an ethical issue in treatment application: biological explanations can reduce blame, but they may also encourage over-medicalisation if psychological needs are ignored.